Financial Data and Key Metrics Changes - Revenue for fiscal Q3 2025 was $58.3 million, a decrease of 4.1% compared to $60.8 million in Q3 2024, but a return to positive quarter-over-quarter organic growth of 1.6% from $57.4 million in Q2 2025 [14][18] - Adjusted EBITDA for Q3 2025 was $13.7 million, or 23.5% of revenue, compared to $14.2 million, or 23.4% of revenue for Q3 2024, representing a 3.6% decrease [14][18] - Net loss for Q3 2025 was $3 million, or $0.07 per diluted share, compared to a loss of $1.6 million, or $0.04 per diluted share for Q3 2024 [15] - Cash flow from operations for the nine months ended June 30, 2025, was $27.9 million, compared to $25.4 million for the same period in 2024 [15] Business Line Data and Key Metrics Changes - The customer base decreased modestly to 151,000 unique patients as of June 30, 2025, from 153,000 unique patients as of June 30, 2024 [13] - Unique setups and deliveries totaled 210,000 in Q3 2025, down from 216,000 in Q3 2024 [13] - Respiratory resupply setups totaled 119,000 in Q3 2025, a slight decrease from 120,000 in the prior year quarter [13] Market Data and Key Metrics Changes - The company reported that recurring revenue for Q3 2025 remained strong at 81% of total revenue [14] - The joint venture with Heart Medical Equipment is expected to enhance the company's presence in the Midwest, particularly in Michigan and Ohio, with access to a recurring patient base of over 67,000 patients each month [20][28] Company Strategy and Development Direction - The company is focused on expanding its healthcare system partnerships, as evidenced by the recent transaction with Ballad Health and the joint venture with Heart Medical Equipment [5][19] - The strategic emphasis on respiratory care aligns with macro trends such as an aging population and rising chronic respiratory disease rates, which are expected to drive long-term demand [23][28] - The company aims to deepen referral networks and enhance operational efficiencies to capture a larger share of patient volume at the point of discharge [26][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's operating metrics and the recent healthcare system transactions, indicating a clear roadmap for growth [9][21] - The company anticipates that the integration of recent acquisitions will lead to improved margins and operational efficiencies [42][44] - Management remains focused on maximizing long-term shareholder value while navigating the evolving healthcare landscape [29] Other Important Information - The company has entered into a joint venture to acquire a 60% ownership stake in Heart Medical Equipment, which generated approximately $60 million in revenue and $7 million in adjusted EBITDA as of June 30, 2025 [19][20] - The company reported a net debt to adjusted EBITDA leverage ratio of 1.5x, well within its target range [17] Q&A Session Summary Question: Can you discuss the adjusted EBITDA margin and targets for improvement? - Management expects continued improvements in EBITDA margins, despite patient CapEx being a drag due to investments in replacing ventilators [31][32] Question: How do you plan to increase the EBITDA margin for the Heart joint venture? - Management anticipates that integration will align Heart's cost structures with Quipt's historical averages, leading to margin improvements [34] Question: What types of patients are being discharged from the health centers? - The majority of patients are treated for respiratory conditions, including ventilation and oxygen needs [35] Question: Is there a financial component to the joint venture? - The joint venture involves an equity position, allowing the company to work closely with hospital systems to enhance discharge processes [38][40] Question: What is the current status of the M&A pipeline? - The M&A pipeline remains strong, with ongoing evaluations of strategic fits for future acquisitions [43][44]

Core Insights - Viemed Healthcare, Inc. reported strong financial results for Q1 2025, with net revenues of $59.1 million, a 17% increase from Q1 2024, and net income of $2.6 million, a 64% increase year-over-year [6][5][19] - The company has updated its full-year 2025 guidance, raising the lower end of its revenue and Adjusted EBITDA ranges due to improved performance across its business segments [5][3] - Viemed announced an agreement to acquire Lehan's Medical Equipment for $26 million, which is expected to enhance its service offerings in respiratory care and women's health [4][6] Financial Performance - Net revenues for Q1 2025 were $59.1 million, up from $50.6 million in Q1 2024, reflecting an increase of $8.5 million [6][19] - Adjusted EBITDA for Q1 2025 was $12.8 million, representing a 26% increase compared to Q1 2024 [6][19] - The company reported a net income of $2.6 million, or $0.06 per diluted share, compared to $1.6 million, or $0.04 per diluted share in the same quarter last year [6][19] Operational Highlights - The number of ventilator patients increased to 11,809, a 13% rise from March 31, 2024 [6][24] - The PAP therapy patient count rose to 22,899, marking a 46% increase year-over-year [6][24] - The sleep resupply patient count was 22,941, a 21% increase from the previous year [6][24] Guidance and Future Outlook - For the full year 2025, net revenue is expected to be in the range of $256 million to $265 million, up from the previous range of $254 million to $265 million [6][3] - Adjusted EBITDA for the year is projected to be between $55 million and $58 million, an increase from the prior range of $54 million to $58 million [6][3] - The anticipated acquisition of Lehan's Medical Equipment is not included in the current guidance but is expected to contribute positively once completed [4][6] Balance Sheet and Cash Flow - As of March 31, 2025, the company had a cash balance of $10.2 million and total assets of $178.1 million [6][17] - Long-term debt stood at $3.5 million, with $55 million available under existing credit facilities [6][17] - The company reported a net cash provided by operating activities of $2.9 million for Q1 2025 [20]